Caregiver input- daratumumab / Europe |
Introduction
Please join us and have your say!
Governments are making decisions about myeloma drug access, be sure your voice is heard!!
Myeloma Canada is seeking input from caregiver who care for people living with myeloma who are not eligible for autologous stem-cell transplant (who have NOT had a transplant as a course of therapy to treat Myeloma), who have used either of the following treatment combinations:
1) bortezomib (Velcade®), melphelan and prednisone (VMP) with daratumumab (Darzalex®)
2) cyclophosphamide, bortezomib (Velcade®), and dexamethasone (CyBorD) with daratumumab (Darzalex®)
Myeloma Canada is seeking input from caregiver who care for people living with myeloma who are not eligible for autologous stem-cell transplant (who have NOT had a transplant as a course of therapy to treat Myeloma), who have used either of the following treatment combinations:
1) bortezomib (Velcade®), melphelan and prednisone (VMP) with daratumumab (Darzalex®)
2) cyclophosphamide, bortezomib (Velcade®), and dexamethasone (CyBorD) with daratumumab (Darzalex®)
To treat their myeloma.
This study is part of the pan Canadian Oncology Drug Review (pCODR) process for this new treatment regimen that will be reviewed in the coming months.Myeloma Canada will provide patient and caregiver input to help decision makers understand the impact of this treatment on patients lives.
pCODR is the national agency that makes funding recommendations to provinces on oncology drugs approved for sale in Canada.
Please note that this survey is meant for caregivers only.
As always, your input is extremely important and, although there is no guarantee, may help to improve the availability and access to important new myeloma drugs for patients across Canada.
This is a very short survey should take about 5 minutes. We ask that you complete the survey by December 10th, 2018.
If you have any questions about this survey, please write to contact@myeloma.ca and include Caregiver Survey in the subject line.
Privacy policy: All survey data are being collected by Myeloma Canada, a national, not for profit, charitable, patient-led group. To ensure patient and caregiver privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used in the final report to pCODR without reference to patient or caregiver name or any other identifying information.
Thank you for your participation and for helping Canadians living with myeloma!
This study is part of the pan Canadian Oncology Drug Review (pCODR) process for this new treatment regimen that will be reviewed in the coming months.Myeloma Canada will provide patient and caregiver input to help decision makers understand the impact of this treatment on patients lives.
pCODR is the national agency that makes funding recommendations to provinces on oncology drugs approved for sale in Canada.
Please note that this survey is meant for caregivers only.
As always, your input is extremely important and, although there is no guarantee, may help to improve the availability and access to important new myeloma drugs for patients across Canada.
This is a very short survey should take about 5 minutes. We ask that you complete the survey by December 10th, 2018.
If you have any questions about this survey, please write to contact@myeloma.ca and include Caregiver Survey in the subject line.
Privacy policy: All survey data are being collected by Myeloma Canada, a national, not for profit, charitable, patient-led group. To ensure patient and caregiver privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used in the final report to pCODR without reference to patient or caregiver name or any other identifying information.
Thank you for your participation and for helping Canadians living with myeloma!